Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Julphar
Queensland Health
Deloitte
Citi
AstraZeneca
Moodys
US Department of Justice
Novartis
Chinese Patent Office

Generated: October 22, 2017

DrugPatentWatch Database Preview

Pimavanserin tartrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pimavanserin tartrate and what is the scope of pimavanserin tartrate freedom to operate?

Pimavanserin tartrate
is the generic ingredient in one branded drug marketed by Acadia Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pimavanserin tartrate has one hundred and forty-two patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for Generic Name: pimavanserin tartrate

US Patents:14
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list52
Clinical Trials: see list153
Patent Applications: see list105
Drug Prices:see low prices
DailyMed Link:pimavanserin tartrate at DailyMed

Pharmacology for Ingredient: pimavanserin tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pimavanserin tartrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,487Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,393,861Derivatives of 4-aminopiperidine and their use as a medicament► Subscribe
7,713,995Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,868,176Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylprop- yloxy)phenylmethyl)carbamide and their preparation► Subscribe
7,790,899Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide and its tartrate salt and crystalline forms► Subscribe
2,017,165,273► Subscribe
7,994,193Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,008,323Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,377,959Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,732,462Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pimavanserin tartrate

Country Document Number Estimated Expiration
South Korea20030011275► Subscribe
BrazilPI0406591► Subscribe
World Intellectual Property Organization (WIPO)2006037043► Subscribe
Japan2003531829► Subscribe
China1207283► Subscribe
Australia2008254238► Subscribe
South Africa201000714► Subscribe
South Korea20070014235► Subscribe
South Korea20070083800► Subscribe
Hong Kong1126776► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Chubb
Teva
Fish and Richardson
Moodys
Argus Health
Deloitte
Novartis
US Army
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot